登陆
当前位置: 首页 >> 检索结果

结果排序

文献格式

出版时间

出版类型

出版语言
共有 87803 条符合本次的查询结果， 用时 2.8921808 秒

1401. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.

作者: James D Chalmers.;Pierre-Régis Burgel.;Charles L Daley.;Anthony De Soyza.;Charles S Haworth.;David Mauger.;Michael R Loebinger.;Pamela J McShane.;Felix C Ringshausen.;Francesco Blasi.;Michal Shteinberg.;Kevin Mange.;Ariel Teper.;Carlos Fernandez.;Migdalia Zambrano.;Chunpeng Fan.;Xiangmin Zhang.;Mark L Metersky.; .
来源: N Engl J Med. 2025年392卷16期1569-1581页
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression. Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP-1), targets neutrophil serine proteases, key mediators of neutrophilic inflammation.

1402. Lorundrostat Efficacy and Safety in Patients with Uncontrolled Hypertension.

作者: Luke J Laffin.;Branko Kopjar.;Carrie Melgaard.;Kathy Wolski.;Jessica Ibbitson.;Shivani Bhikam.;Matthew R Weir.;Elizabeth O Ofili.;Reena Mehra.;James M Luther.;Debbie L Cohen.;Ashish Sarraju.;Michael J Wilkinson.;John M Flack.;David Rodman.;Steven E Nissen.; .
来源: N Engl J Med. 2025年392卷18期1813-1823页
Aldosterone dysregulation contributes to hypertension. Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited.

1403. Climate Change and Human Health - A Research Agenda for Action.

作者: Victor J Dzau.;Melissa H Laitner.;Celynne A Balatbat.;Shaneah Taylor.
来源: N Engl J Med. 2025年393卷1期88-92页

1404. Pavement Burns.

作者: Jeremy J Hess.
来源: N Engl J Med. 2025年392卷16期e40页

1405. Clearing the Smoke on Fossil Fuels - The Health Imperative for a Countermarketing Campaign.

作者: Linda Rudolph.;Vishnu Laalitha Surapaneni.
来源: N Engl J Med. 2025年392卷16期1563-1565页

1406. EPSDT - Medicaid's Mandate for Children and Adolescents.

作者: James M Perrin.;Joan C Alker.;Cindy Mann.
来源: N Engl J Med. 2025年392卷16期1565-1567页

1407. An HIV Vaccine in the Era of Twice-Yearly Lenacapavir for PrEP - Essential or Irrelevant?

作者: Lauren P Jatt.;Nyaradzo M Mgodi.;Susan P Buchbinder.;Glenda E Gray.;James G Kublin.
来源: N Engl J Med. 2025年392卷16期1561-1563页

1408. "Putting America First" - Undermining Health for Populations at Home and Abroad.

作者: Christopher P Duggan.;Zulfiqar A Bhutta.
来源: N Engl J Med. 2025年392卷18期1769-1771页

1409. Hemophagocytic Lymphohistiocytosis. Reply.

作者: Jan-Inge Henter.
来源: N Engl J Med. 2025年392卷15期1559-1560页

1410. Hemophagocytic Lymphohistiocytosis.

作者: Jon Hoover.
来源: N Engl J Med. 2025年392卷15期1558-1559页

1411. Hemophagocytic Lymphohistiocytosis.

作者: R Ward Hagar.
来源: N Engl J Med. 2025年392卷15期1558页

1412. Hemophagocytic Lymphohistiocytosis.

作者: Luke Y C Chen.;Mariam Goubran.;Caroline Spaner.
来源: N Engl J Med. 2025年392卷15期1557-1558页

1413. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation. Reply.

作者: Christian T Ruff.;Erica L Goodrich.;Marc S Sabatine.
来源: N Engl J Med. 2025年392卷15期1557页

1414. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.

作者: Emanuel Raschi.;Alessandro Squizzato.
来源: N Engl J Med. 2025年392卷15期1556-1557页

1415. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.

作者: Christopher Henry.
来源: N Engl J Med. 2025年392卷15期1556页

1416. Fracture Prevention with Infrequent Zoledronate in Women. Reply.

作者: Mark J Bolland.;Ian R Reid.;Andrew Grey.
来源: N Engl J Med. 2025年392卷15期1555-1556页

1417. Fracture Prevention with Infrequent Zoledronate in Women.

作者: Param Darpan Sheth.
来源: N Engl J Med. 2025年392卷15期1555页

1418. Fracture Prevention with Infrequent Zoledronate in Women.

作者: Edy Kornelius.
来源: N Engl J Med. 2025年392卷15期1554-1555页

1419. Perioperative Chemotherapy in Esophageal Cancer. Reply.

作者: Jens Hoeppner.;Claudia Schmoor.;Florian Lordick.
来源: N Engl J Med. 2025年392卷15期1554页

1420. Perioperative Chemotherapy in Esophageal Cancer.

作者: Jie Qin.;Bei Feng.;Juanjuan Huang.
来源: N Engl J Med. 2025年392卷15期1554页
共有 87803 条符合本次的查询结果， 用时 2.8921808 秒